Cancer diagnosis linked to high rates of alcohol use, plus more top stories in hematology/oncology
Click Here to Manage Email Alerts
A feature on new study data showing over half of patients with a history of cancer diagnosis report high rates of alcohol consumption was the top story in hematology/oncology last week.
Another top story looked at research published in The Lancet Oncology showing that cancer survivors who were diagnosed during adolescence or early adulthood appeared to be at a greater risk for mortality and severe chronic health conditions compared with the general population.
Read these and more of last week’s stop stories in hematology/oncology below:
Patients with cancer, survivors report high rates of alcohol use
A large study of drinking habits in the oncology population revealed high rates of alcohol consumption among patients with and survivors of cancer. Read more.
Adolescent, young adult cancer survivors at higher risk for mortality, chronic conditions
Survivors of cancer diagnosed during adolescence or early adulthood appeared at greater risk for mortality and severe chronic health conditions compared with the general population, according to results of a retrospective study published in The Lancet Oncology. Read more.
Timing, patterns of relapse predict survival after HSCT for multiple myeloma
Time to relapse appeared prognostic for survival among individuals with multiple myeloma who underwent CD34 positive-selected allogeneic hematopoietic stem cell transplantation, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings. Read more.
CAR-T confers long-term quality-of-life improvement among patients with advanced lymphoma
Patients with relapsed or refractory diffuse large B-cell lymphoma experienced clinically meaningful improvements in long-term quality-of-life measurements after responding to an infusion of tisagenlecleucel, according to a post hoc analysis of patient-reported outcomes in the JULIET trial published in Blood Advances. Read more.
Novel small-molecule inhibitor ‘quite promising’ in advanced kidney cancer
MK-6482 appeared well-tolerated and showed promising single-agent activity among heavily pretreated patients with clear cell renal cell carcinoma, according to results of a first-in-human phase 1/phase 2 study presented at Genitourinary Cancers Symposium. Read more.